ArticleFrontiers in immunology2026
Case Report: Teprotumumab treatment in an HIV-infected patient with refractory thyroid eye disease: clinical and quantitative MRI evidence.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: People living with human immunodeficiency virus (HIV) may develop Graves' disease as a delayed autoimmune manifestation of immune reconstitution inflammatory syndrome following antiretroviral therapy. Thyroid eye disease (TED) is uncommon in this setting. Teprotumumab targets the insulin-like growth factor-1 receptor (IGF-1R) and inhibits orbital fibroblast activation; however, its use in patients with HIV-associated TED has not previously been reported. Case presentation: A 37-year-old man with HIV infection developed Graves' hyperthyroidism and active moderate-to-severe TED five years after HIV diagnosis. Disease activity recurred after intravenous glucocorticoids and tocilizumab and persisted despite bilateral orbital decompression. At initial presentation, the CD4 Results: After three teprotumumab infusions, the clinical activity score decreased from 3/7 to 1/7 in both eyes. Proptosis decreased from 21 mm in the right eye and 22 mm in the left eye to 20 mm bilaterally, and extraocular motility and diplopia improved. Quantitative magnetic resonance imaging (MRI) showed reductions in medial rectus diameter and apparent diffusion coefficient values. Systemic immune recovery remained incomplete, but no opportunistic infections, HIV-related clinical deterioration, infusion reactions, or clinically evident hearing impairment were observed. Conclusion: This case suggests that teprotumumab may improve clinical and imaging outcomes in selected patients with refractory HIV-associated TED despite incomplete systemic immune recovery. The relative dissociation between orbital improvement and conventional systemic immune indices suggests that local IGF-1R-dependent mechanisms may contribute to treatment response. Further studies are required to determine long-term efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.